Prostate cancer (PCa) is the most common solid neoplasm diagnosed in developed countries.
Nerve-sparing radical prostatectomy (NS-RP) has been widely accepted as the best choice treatment for localised PCa. However, erectile dysfunction (ED) and urinary incontinence are commonly observed after NS-RP. Using meta-analysis, we examined if phosphodiesterase type 5 inhibitors (PDE5-Is) could improve the symptoms of ED in patients undergoing NS-RP. This review contained seven randomised placebo-controlled trials with a total of 2,655 male patients. Patients in PDE5-Is group showed significant improvement in the International Index of Erectile Function-Erectile Function domain score (IIEF-EF), Global Assessment Questionnaire (GAQ), Sexual Encounter Profile question 2 (SEP-2) and SEP-3. Although the incidence of treatment-emergent adverse events (TEAEs) were high in both groups (56.44% vs. 40.63%), the safety profile were acceptable, with low incidence of discontinuation rate due to adverse events. Therefore, PDE5-Is are recommended for the treatment of post-NS-RP ED. Patients should be informed of possible adverse events.
Written by:
Li J, Shi Q, Pu C, Tang Y, Bai Y, Yuan H, Li X, Dong Q, Wei Q, Yuan J, Han P. Are you the author?
Department of Urology, West China hospital, Sichuan University, Chengdu, China; Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China.
Reference: Sci Rep. 2014 Jul 23;4:5801.
doi: 10.1038/srep05801.
PubMed Abstract
PMID: 25052550
UroToday.com Erectile Dysfunction Section
